Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176277 · ClinicalTrials.gov registry record · Phase 1
A Study of ONO-7475 in Patients With Acute Leukemias
A Phase 1 study, sponsored by Ono Pharmaceutical Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03176277 is a Phase 1 study that was terminated before completion, run by Ono Pharmaceutical Co.. The registered enrollment target is 42 participants.
The verdict
NCT03176277, a Phase 1 study, was terminated before completion, sponsored by Ono Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
\[Updated\]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability and ii) preliminary efficacy of the combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid leukemia.
Interventions
- DRUG ONO-7475 3mg once daily
- DRUG ONO-7475 6mg once daily
- DRUG ONO-7475 10mg once daily
- DRUG ONO-7475 6mg + Venetoclax (70-400mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-06-26 |
| Est. Completion | 2023-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03176277
The ClinicalTrials.gov registry entry for NCT03176277 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ONO-7475 3mg once daily is the first listed.
NCT03176277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03176277 about?
NCT03176277 is a clinical study titled "A Study of ONO-7475 in Patients With Acute Leukemias". \[Updated\]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability and ii) preliminary efficacy of the combination of ONO-7475 and vene...
What is the current status of trial NCT03176277?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-06-26. Estimated completion is 2023-01-20.
What interventions are being tested in trial NCT03176277?
The interventions under investigation include: ONO-7475 3mg once daily (DRUG), ONO-7475 6mg once daily (DRUG), ONO-7475 10mg once daily (DRUG), ONO-7475 6mg + Venetoclax (70-400mg) (DRUG).
Who is sponsoring clinical trial NCT03176277?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.